Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd
"Astrazeneca Pharma India Limited has received permission for import and market for cancer drug i.e Acalabrutinib 100mg capsules (Calquence ®) from the Drugs Controller General of India in Form CT-20 (Marketing Authorization- Additional Indication). AstraZeneca Pharma India Limited will launch Calquence® in India on October 21, 2020. Acalabrutinib 100mg capsules Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy or indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL). This is positive development for Astrazeneca Pharma India Limited."
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.4280 as compared to the previous close of Rs. 4292.65. The total number of shares traded during the day was 2557 in over 736 trades.
The stock hit an intraday high of Rs. 4300 and intraday low of 4220. The net turnover during the day was Rs. 10885489.